Opinion on Pharmaceuticals and Healthcare in Spain

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
ResearchWire
ResearchWire

Anticonvulsants: potential sales growth in off-label expansion

Published By Datamonitor
31 Jul 2001
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001
ResearchWire
ResearchWire

Antimetabolites: market will be worth $1.9 billion in 2007

Published By Datamonitor
12 Jun 2001
ResearchWire
ResearchWire

Antipsychotics: growth in sales but only until 2006

Published By Datamonitor
20 Apr 2001
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.